Pentadeca Arginate vs BPC-157

Side-by-side comparison of Pentadeca Arginate, BPC-157 — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute Pentadeca Arginate Pentadeca Arginate (PDA) — BPC-157 Arginine Variant Recovery BPC-157 Body Protection Compound-157 Recovery
Basics
Molecular type Pentadecapeptide Arginine AnalogueGastric Pentadecapeptide
Amino acids 1515
Molecular weight 1,476.6 Da1,419.5 Da
Half-life ~4–6 hrs (estimated)~4 hrs (SC)
Route(s) Subcutaneous, Intramuscular, Oral (research)Subcutaneous, Intramuscular, Oral (research only)
Mechanism & Research
Primary mechanism PDA shares BPC-157's primary mechanism of action: nitric oxide (NO) synthase upregulation, VEGFR2-mediated angiogenesis, and connective tissue repair signalling. The arginine modification may further amplify NO pathway a… BPC-157 exerts its primary effects through upregulation of the nitric oxide (NO) signalling pathway. By promoting NO synthase activity, it drives vasodilation and angiogenesis at injury sites, accelerating the delivery o…
Research status Research Compound Research Compound
Evidence summary PDA is a newer research compound with a smaller published evidence base than BPC-157. Most researchers extrapolate from BPC-157's extensive preclinical data given the structural and mechanistic similarity. Direct compara… The majority of BPC-157 research is preclinical (animal and in vitro). No large-scale randomised controlled trials in humans have been published as of 2026. The FDA's 2024 assessment noted insufficient human safety and e…
Protocol & Dosing
Typical dose 200–500 mcg per injection200–500 mcg per injection
Frequency Once or twice dailyOnce or twice daily
Duration 4–12 weeks4–12 weeks
Timing Near injury site when possible; any timeNear injury site when possible
Safety
Common side effects
  • Injection site redness or bruising
  • Mild nausea (oral form)
  • Transient dizziness
  • Warmth at injection site
  • Injection site redness or bruising
  • Mild nausea (oral form)
  • Transient dizziness
  • Warmth at injection site
Contraindications
  • Active malignancy (angiogenesis concern)
  • Pregnancy (no safety data)
  • Concurrent anticoagulant therapy (caution)
  • Active malignancy (theoretical growth stimulation concern)
  • Pregnancy (no safety data)
  • Concurrent anticoagulant therapy (caution)
Anti-doping Prohibited (WADA S0) Prohibited (WADA S0)
Deeper reading
Related peptides BPC-157, TB-500, GHK-Cu TB-500, GHK-Cu, KPV, Pentadeca Arginate
Full profile Read full Pentadeca Arginate profile → Read full BPC-157 profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.